安徽医药
安徽醫藥
안휘의약
ANHUI MEDICAL AND PHARMACEUTICAL JOURNAL
2015年
1期
82-86
,共5页
叶勇%马金良%余继海%许戈良%李建生%荚卫东
葉勇%馬金良%餘繼海%許戈良%李建生%莢衛東
협용%마금량%여계해%허과량%리건생%협위동
门静脉高压症%断流术%血必净
門靜脈高壓癥%斷流術%血必淨
문정맥고압증%단류술%혈필정
portal hypertension%devascularization%xuebijing
目的:探讨血必净在门静脉高压症断流术后应用的效果。方法在该院近2年诊断为肝炎后门静脉高压症接受脾切除+断流术治疗的患者中选择46例随机分为研究组和对照组,研究组术后使用血必净,对照组术后常规治疗。检测两组术前及术后1、3、5、7 d 肝功能指标、凝血功能指标、免疫指标、炎症反应指标并观察术后并发症。结果两组患者术后结合胆红素(DBil)、凝血酶原时间(PT)、T 淋巴细胞亚群 CD4+、CD8+、免疫球蛋白 IgG、IgM、C 反应蛋白(CRP)及门静脉血栓发生例数差异有统计学意义(P <0.05)。结论门静脉高压症患者术后使用血必净可提高机体免疫力、减轻炎症反应、减少术后并发症及门静脉血栓的发生率。
目的:探討血必淨在門靜脈高壓癥斷流術後應用的效果。方法在該院近2年診斷為肝炎後門靜脈高壓癥接受脾切除+斷流術治療的患者中選擇46例隨機分為研究組和對照組,研究組術後使用血必淨,對照組術後常規治療。檢測兩組術前及術後1、3、5、7 d 肝功能指標、凝血功能指標、免疫指標、炎癥反應指標併觀察術後併髮癥。結果兩組患者術後結閤膽紅素(DBil)、凝血酶原時間(PT)、T 淋巴細胞亞群 CD4+、CD8+、免疫毬蛋白 IgG、IgM、C 反應蛋白(CRP)及門靜脈血栓髮生例數差異有統計學意義(P <0.05)。結論門靜脈高壓癥患者術後使用血必淨可提高機體免疫力、減輕炎癥反應、減少術後併髮癥及門靜脈血栓的髮生率。
목적:탐토혈필정재문정맥고압증단류술후응용적효과。방법재해원근2년진단위간염후문정맥고압증접수비절제+단류술치료적환자중선택46례수궤분위연구조화대조조,연구조술후사용혈필정,대조조술후상규치료。검측량조술전급술후1、3、5、7 d 간공능지표、응혈공능지표、면역지표、염증반응지표병관찰술후병발증。결과량조환자술후결합담홍소(DBil)、응혈매원시간(PT)、T 림파세포아군 CD4+、CD8+、면역구단백 IgG、IgM、C 반응단백(CRP)급문정맥혈전발생례수차이유통계학의의(P <0.05)。결론문정맥고압증환자술후사용혈필정가제고궤체면역력、감경염증반응、감소술후병발증급문정맥혈전적발생솔。
Objective To investigate the effects of Xuebijing in patients of portal hypertension after devascularization operations.Meth-ods Forty-six patients of devascularization were randomized into two groups:group A was Xuebijing treatment group (n =23),and group B was conventional treatment group (n =23).Preoperative and postoperative 1,3,5,7 d ALT,PT,TBIL,CRP,PVT and other in-dicators of patients in both groups were detected to determine the recovery of liver function.Results The total number of cases of post-operative differences in the two groups of bilirubin (DBil),prothrombin time (PT),T lymphocyte subsets CD4 +、CD8 +,immunoglobu-lins IgG,IgM,C-reactive protein (CRP)and portal vein thrombosis there was statistically significant (P <0.05).Conclusions Post-operative patients with portal hypertension using Xuebijing can improve immunity,reduce inflammation,reduce postoperative complica-tions and the incidence of portal vein thrombosis.